Summary
| Direction in Long COVID | ↑ Elevated — higher than in the comparison group |
|---|---|
| Category | Immune |
| Also described as | Type I IFN autoAbs |
| Compared against | HC (healthy controls) |
| Associated symptoms | Immune dysregulation |
| Test type | Blood test (serum / plasma / whole blood) |
| Source | Wilhelm et al. 2026 — doi:10.1016/S1473-3099(25)00411-6 |
| Condition atlas | Long COVID Biomarker Atlas |
Related Immune markers in Long COVID
- Anti-IFN-ω autoantibodies ↑
- Anti-GPCR autoantibodies ↑
- β2-microglobulin ↑
- Complement C3a / C5a ↑
- T cell exhaustion markers ↑
- Low naive T cells / High effector memory ↕
Full list: Long COVID Biomarker Atlas.
Frequently asked questions
Is Anti-IFN-α autoantibodies high or low in Long COVID?
Elevated. Studies summarised in the OSMF atlas report higher Anti-IFN-α autoantibodies in Long COVID than in healthy controls. Source: Wilhelm et al. 2026.
What symptoms is Anti-IFN-α autoantibodies associated with in Long COVID?
The cited literature associates this marker with Immune dysregulation. These are population-level associations and do not mean the marker causes the symptoms.
Which test measures Anti-IFN-α autoantibodies?
It is measured as a blood test (serum / plasma / whole blood). Many of the cited studies used research-grade assays, so clinical availability may vary.
Is one abnormal Anti-IFN-α autoantibodies result diagnostic of Long COVID?
No. No single biomarker is diagnostic of Long COVID. Anti-IFN-α autoantibodies findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.
Cite this page
Subscribe on Substack
Last reviewed: 2026-06-29 · Page generated from long-covid.json · Browse: Long COVID atlas · Biomarker Index · All marker pages
Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.